Loading…
MRNA · NASDAQ · Biotechnology
Everything reported about this company, newest first. Each line shows the dates that matter for its source.
Insider trade · Traded Sep 15, 2026 · Filed Sep 16, 2026
Officer sold ~$5.88M of MRNA shares in the open marketSourceInsider trade · Traded Sep 14, 2026 · Filed Sep 16, 2026
Officer sold ~$5.81M of MRNA shares in the open marketSourcePlanned sale · Planned for Sep 15, 2026 · Notice filed Sep 15, 2026
Officer filed to sell about $5.88M of MRNA stockSourceInsider trade · Traded Sep 10, 2026 · Filed Sep 14, 2026
CFO sold ~$2.67M of MRNA shares in the open marketSourceInsider trade · Traded Sep 10, 2026 · Filed Sep 14, 2026
CFO sold ~$2.02M of MRNA shares in the open marketSourcePlanned sale · Planned for Sep 14, 2026 · Notice filed Sep 14, 2026
Officer filed to sell about $5.81M of MRNA stockSourcePlanned sale · Planned for Sep 10, 2026 · Notice filed Sep 10, 2026
Officer filed to sell about $4.69M of MRNA stockSourceCongressional trade · Transaction Aug 19, 2026 · Disclosed Sep 9, 2026
Disclosed partial sale of MRNA — reported range $1,001 - $15,000SourceCongressional trade · Transaction Aug 19, 2026 · Disclosed Sep 9, 2026
Disclosed purchase of MRNA — reported range $1,001 - $15,000SourceInsider trade · Traded Sep 1, 2026 · Filed Sep 3, 2026
Officer sold ~$486K of MRNA shares in the open marketSourceFund moves · Holdings as of Jun 30, 2026 (Q2 2026) · Filed Aug 14, 2026
Bridgewater Associates disclosed a reduced position in MRNA for Q2 2026Source5%+ stake · Stake as of Jun 30, 2026 · Filed Aug 12, 2026
Capital World Investors now owns 5.6% of MRNA as a passive investorSourceInsider trade · Traded Aug 5, 2026 · Filed Aug 7, 2026
CEO sold ~$11M of MRNA shares in the open marketSourceInsider trade · Traded Aug 5, 2026 · Filed Aug 7, 2026
CEO sold ~$8.29M of MRNA shares in the open marketSource5%+ stake · Stake as of Jun 30, 2026 · Filed Jul 24, 2026
BAILLIE GIFFORD & CO cut its MRNA stake below 5% (4.6%)SourceInsider trade · Traded Jul 15, 2026 · Filed Jul 16, 2026
Officer sold ~$3.61M of MRNA shares in the open marketSourceInsider trade · Traded Jun 15, 2026 · Filed Jun 17, 2026
Officer sold ~$2.74M of MRNA shares in the open marketSourceInsider trade · Traded Jun 4, 2026 · Filed Jun 8, 2026
Officer sold ~$174K of MRNA shares in the open marketSourceInsider trade · Traded May 21, 2026 · Filed May 22, 2026
Director sold ~$434K of MRNA shares in the open marketSourceInsider trade · Traded May 15, 2026 · Filed May 18, 2026
Officer sold ~$2.58M of MRNA shares in the open marketSourceInsider trade · Traded May 1, 2026 · Filed May 4, 2026
Director sold ~$265K of MRNA shares in the open marketSourceInsider trade · Traded Mar 2, 2026 · Filed Mar 3, 2026
Officer sold ~$726K of MRNA shares in the open marketSourceInsider trade · Traded Feb 23, 2026 · Filed Feb 25, 2026
Officer sold ~$7.81M of MRNA shares in the open marketSourceInsider trade · Traded Dec 11, 2025 · Filed Dec 15, 2025
Director sold ~$703K of MRNA shares in the open marketSourceInsider trade · Traded Dec 9, 2025 · Filed Dec 11, 2025
Director sold ~$14K of MRNA shares in the open marketSourceCongressional trade · Transaction Apr 8, 2025 · Disclosed May 8, 2025
Disclosed sale of MRNA — reported range $1,001 - $15,000SourceCongressional trade · Transaction Feb 25, 2025 · Disclosed Mar 27, 2025
Disclosed purchase of MRNA — reported range $1,001 - $15,000SourceCongressional trade · Transaction Jan 15, 2025 · Disclosed Feb 12, 2025
Disclosed sale of MRNA — reported range $1,001 - $15,000SourceInsider trade · Traded Aug 5, 2026 · Filed Aug 7, 2026
CEO sold ~$7.11M of MRNA shares in the open marketSourceInsider trade · Traded Aug 5, 2026 · Filed Aug 7, 2026
CEO sold ~$2.32M of MRNA shares in the open marketSource